Cognitive impairment in patients with cerebrovascular disease: A white paper from the links between stroke ESO Dementia Committee
- PMID: 33817330
- PMCID: PMC7995319
- DOI: 10.1177/23969873211000258
Cognitive impairment in patients with cerebrovascular disease: A white paper from the links between stroke ESO Dementia Committee
Abstract
Purpose: Many daily-life clinical decisions in patients with cerebrovascular disease and cognitive impairment are complex. Evidence-based information sustaining these decisions is frequently lacking. The aim of this paper is to propose a practical clinical approach to cognitive impairments in patients with known cerebrovascular disease.
Methods: The document was produced by the Dementia Committee of the European Stroke Organisation (ESO), based on evidence from the literature where available and on the clinical experience of the Committee members. This paper was endorsed by the ESO.
Findings: Many patients with stroke or other cerebrovascular disease have cognitive impairment, but this is often not recognized. With improvement in acute stroke care, and with the ageing of populations, it is expected that more stroke survivors and more patients with cerebrovascular disease will need adequate management of cognitive impairment of vascular etiology. This document was conceived for the use of strokologists and for those clinicians involved in cerebrovascular disease, with specific and practical hints concerning diagnostic tools, cognitive impairment management and decision on some therapeutic options.Discussion and conclusions: It is essential to consider a possible cognitive deterioration in every patient who experiences a stroke. Neuropsychological evaluation should be adapted to the clinical status. Brain imaging is the most informative biomarker concerning prognosis. Treatment should always include adequate secondary prevention.
Keywords: Stroke; cerebrovascular disease; cognitive impairment; dementia; small vessel disease.
© European Stroke Organisation 2021.
Conflict of interest statement
Declaration of conflicting interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Olivier Godefroy during the last five years has served on scientific advisory boards and speaker (Biogen, Astra Zeneca, Novartis) and received funding for travel and meetings from Bristol-Myers Squibb, Roche, Biogen, Teva-santé, Boehringer-Ingelheim, Covidien, Ipsen. The remaining authors declare that there are no conflict of interest concerning the paper.
References
-
- Livingston G, Sommerlad A, Orgeta V, et al.. Dementia prevention, intervention, and care. Lancet 2017; 390: 2673–2734. - PubMed
-
- Pollock A, St George B, Fenton M, et al.. Top 10 research priorities relating to life after stroke–consensus from stroke survivors, caregivers, and health professionals. Int J Stroke 2014; 9: 313–320. - PubMed
-
- Román GC, Tatemichi TK, Erkinjuntti T, et al.. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993; 43: 250–260. - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources